On Tuesday, Day One Biopharmaceuticals Inc (NASDAQ: DAWN) opened higher 2.15% from the last session, before settling in for the closing price of $6.74. Price fluctuations for DAWN have ranged from $6.08 to $16.76 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -38.09%. Company’s average yearly earnings per share was noted -29.24% at the time writing. With a float of $74.67 million, this company’s outstanding shares have now reached $101.35 million.
The extent of productivity of a business whose workforce counts for 181 workers is very important to gauge. In terms of profitability, gross margin is 94.96%, operating margin of -118.31%, and the pretax margin is -38.25%.
Day One Biopharmaceuticals Inc (DAWN) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Day One Biopharmaceuticals Inc is 26.33%, while institutional ownership is 84.41%. The most recent insider transaction that took place on May 16 ’25, was worth 24,575. In this transaction Chief Commercial Officer of this company sold 3,927 shares at a rate of $6.26, taking the stock ownership to the 35,161 shares. Before that another transaction happened on May 16 ’25, when Company’s GENERAL COUNSEL sold 4,552 for $6.26, making the entire transaction worth $28,486. This insider now owns 47,136 shares in total.
Day One Biopharmaceuticals Inc (DAWN) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -29.24% per share during the next fiscal year.
Day One Biopharmaceuticals Inc (NASDAQ: DAWN) Trading Performance Indicators
Check out the current performance indicators for Day One Biopharmaceuticals Inc (DAWN). In the past quarter, the stock posted a quick ratio of 10.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.31.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.67, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -0.77 in one year’s time.
Technical Analysis of Day One Biopharmaceuticals Inc (DAWN)
The latest stats from [Day One Biopharmaceuticals Inc, DAWN] show that its last 5-days average volume of 1.97 million was superior to 1.3 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 33.98%.
During the past 100 days, Day One Biopharmaceuticals Inc’s (DAWN) raw stochastic average was set at 28.47%, which indicates a significant decrease from 51.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.30 in the past 14 days, which was lower than the 0.38 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.71, while its 200-day Moving Average is $9.90.
